Using mouse transgenic and human stem cell technologies to model genetic mutations associated with schizophrenia and autism by Clair, David St & Johnstone, Mandy
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using mouse transgenic and human stem cell technologies to
model genetic mutations associated with schizophrenia and
autism
Citation for published version:
Clair, DS & Johnstone, M 2018, 'Using mouse transgenic and human stem cell technologies to model
genetic mutations associated with schizophrenia and autism', Philosophical Transactions of the Royal
Society B: Biological Sciences. https://doi.org/10.1098/rstb.2017.0037
Digital Object Identifier (DOI):
10.1098/rstb.2017.0037
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Philosophical Transactions of the Royal Society B: Biological Sciences
Publisher Rights Statement:
© 2018 The Authors.
Published by the Royal Society under the terms of the Creative Commons Attribution License
http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original author and
source are credited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
 on January 23, 2018http://rstb.royalsocietypublishing.org/Downloaded from rstb.royalsocietypublishing.orgReview
Cite this article: St. Clair D, Johnstone M.
2018 Using mouse transgenic and human
stem cell technologies to model genetic
mutations associated with schizophrenia and
autism. Phil. Trans. R. Soc. B 373: 20170037.
http://dx.doi.org/10.1098/rstb.2017.0037
Accepted: 2 November 2017
One contribution of 16 to a discussion meeting
issue ‘Of mice and mental health: facilitating
dialogue between basic and clinical
neuroscientists’.
Subject Areas:
genetics, neuroscience
Keywords:
Schizophrenia, autism, mouse and iPSC models
Author for correspondence:
David St. Clair
e-mail: d.stclair@abdn.ac.uk& 2018 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.Using mouse transgenic and human
stem cell technologies to model genetic
mutations associated with schizophrenia
and autism
David St. Clair1 and Mandy Johnstone2,3,4
1Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK
2Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
3Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine,
University of Edinburgh, Edinburgh, UK
4Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
DStC, 0000-0002-5890-7292; MJ, 0000-0002-8398-0862
Solid progress has occurred over the last decade in our understanding of the
molecular genetic basis of neurodevelopmental disorders, and of schizophrenia
and autism in particular. Although the genetic architecture of both disorders
is far more complex than previously imagined, many key loci have at last
been identified. This has allowed in vivo and in vitro technologies to be refined
to model specific high-penetrant genetic loci involved in both disorders.
Using the DISC1/NDE1 and CYFIP1/EIF4E loci as exemplars, we explore
the opportunities and challenges of using animal models and human-induced
pluripotent stem cell technologies to further understand/treat and potentially
reverse the worst consequences of these debilitating disorders.
This article is part of a discussion meeting issue ‘Of mice and mental
health: facilitating dialogue between basic and clinical neuroscientists’.1. Introduction
Schizophrenia (SCZ) and autism (ASD) are two of the most important neuro-
developmental disorders encountered in routine clinical psychiatric practice.
Both are diagnosed on the basis of clinical history, symptoms and behaviour.
These include SCZ-positive symptoms, such as hallucinations, delusions and
thought disorder, and SCZ-negative symptoms such as social withdrawal anhe-
donia and poverty of thought: there are also a range of cognitive abnormalities
especially of attention, memory and executive function. ASD is characterized
by abnormalities of social communication and interaction and repetitive patterns
of interests and behaviour. Unfortunately, in spite of intensive efforts spanning
several decades, there are still no objective tests (biomarkers) in routine clinical
psychiatric practice to assist with diagnosis of any psychiatric disorders including
SCZ andASD [1]. Although ages of clinical presentation of SCZ andASD are nor-
mally early adult life and early infancy, respectively, both have at least in part
neurodevelopmental origins, namely antecedents affecting brain development,
and, in turn, predisposition to one or both disorders can occur at any point in
the life cycle probably from conception onwards. There are also pre-conceptual
intergenerational effects, the most studied being parental and grandparental
age. Antecedents may be environmental or genetic/epigenetic or the effects of
gene–environment (G  E) interactions. Environmental risk factors are often dis-
cussed in the context of a ‘stress-vulnerability’ aetiological model where early
biological and psychological insults, occurring in both the pre- and postnatal
periods, result in changes of gene and protein expression, and/or changes in
the intracellular and extracellular milieu of the developing brain. For recent
rstb.royalsociet
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ever, perhaps, the most intriguing finding to emerge from
epidemiological studies is that SCZ and ASD appear to share
a remarkable number of environmental risk factors [4,5]. A
similar pattern of overlapping genetic risk profiles for SCZ
and ASD will be discussed below. ypublishing.org
Phil.Trans.R.Soc.B
373:201700372. Familiarity
SCZ and ASD are both strongly familial neuropsychiatric
disorders. The evidence in SCZ comes from multiple twin
family and adoption studies and points to a heritability of up
to 80% with monozygotic concordance of 40–50% [6,7].
There have been many fewer twin and family studies of ASD
and surprisingly no adoption studies. Earlier twin studies
suggested heritability as high as 80–90% for ASD with little
contribution from the environment [8]. Newer studies of MZ
twins have yielded concordance rates of less than 50%, with
lower concordance for dizygotic twins, suggesting that both
genes and environment play roles in the development of
ASD [9]. The current consensus is that up to 40–50% of
variance is determined by environmental factors [2].
Early linkage and candidate gene mapping studies of SCZ
and ASD have yielded little in the way of findings that have
stood the test of time. The most studied are disrupted in schizo-
phrenia one (DISC1 gene) identified by cloning the breakpoints
of a balanced 1 : 11 chromosomal rearrangement associated
with multiple cases of mental illness including SCZ in a large
Scottish pedigree [10], chromosome 22 deletion syndrome
associated with a range of severe neurodevelopmental dis-
orders [11], fragile  syndrome [12], Rett syndrome [13] and
rare cases of ASD with mutations of neuroligin genes [14].
Our understanding of the genetic architecture of neurodeve-
lopmental disorders expanded enormously with the advent of
methods for systematic interrogation of DNA across the whole
genome, first through genome-wide association studies
(GWAS) and more recently whole exome and whole genome
sequencing. It allows us to detect association with rare (less
than 1%) high-penetrant genetic lesions including copy
number variants (CNVs) and association with common low-
penetrant genetic risk factors identified using single-nucleotide
polymorphism (SNP) microarrays. These latter common low-
penetrant risk factors have odds ratios approximately 1.0–1.2.
Rare low-penetrant genetic lesions also exist, but sample sizes
required for their detection with reasonable statistical support-
ing evidence are far beyond those currently available
worldwide; a similar problem confounds potential genome-
wide studies of gene/gene interactions/epistasis [15]. It is also
possible to examine non-statistically significant common var-
iants for association as a whole so-called polygenic liability
risk [16]. This latter approachdoes not, however, helpwith selec-
tion of individual gene targets for in vivo or in vitromodelling.
(a) Rare variants
The genetic findings in both SCZ andASD are broadly similar.
In both disorders, there is enormous genetic heterogeneity, but
only a small proportion (5–10%) of the overall genetic risk
results from rare high-penetrant genetic mutations including
CNVs. Many of these latter loci (causing deletions or dupli-
cations of stretches of DNA) show pleiotropy, i.e. they
display a range of clinical phenotypic abnormalities that
include ASD, intellectual impairment, SCZ and epilepsy[17]. This means that there is considerable overlap of high-
penetrant loci between SCZ and ASD. Many mutations,
especially in ASD, have arisen de novo and are not found in
the parents of the affected proband [18–21]. This reflects the
fact that they are heavily selected against due to the reduced
fecundity associated with neurodevelopmental disorders. In
ASD, this is so pronounced that it is almost impossible to
find families with ASD in more than two generations. In
SCZ, familial cases are more common but with high-penetrant
loci, the effects of reduced fecundity are also clinically observa-
ble. This was elegantly demonstrated in the Icelandic
population where it was possible to examine formally family
inheritance patterns of recurrent non-de novo SCZ-associated
CNVs. Although recurrent CNVs have high mutation rates
due to non-allelic homologous recombination, they are elimi-
nated fast by negative selection and seldom survive more
than two or three generations [22]. Around 800 rare loci are
reported in ASD (far fewer in SCZ), but the evidence to sup-
port their causal involvement varies enormously and in only
a few dozen including recurrent CNVs is there statistical evi-
dence of genetic association [19]. Among these genes are
NGLN4X [14], SHANK3 [23,24], NRXN1 [25,26], SHANK2
[27], CNTN4 [28–30] and CNTNAP2 [31,32]. The findings in
SCZ are broadly similar [33–35].
(b) Common variants
Initial genome-wide SCZ SNP association studies, involving
several thousand cases and controls, yielded only two or
three loci that meet statistical significance (p, 1  1027.5–8),
the precise significance level depending on the number of
tests performed [16,22]. However with increased sample sizes
to around 150,000 individuals, over 100 loci were reported to
meet genome wide significance [36] with additional loci being
subsequently reported [37]. Although multiple common low-
risk variants are reported associated with ASD, to date no loci
for ASD have consistently met criteria for genome-wide signifi-
cant association; this is probably the result of inadequate
sample sizes. There are a number of excellent articles discussing
gene/gene interactions/epistasis [15], SCZ epigenetics [38] and
modelling of polygenic risk [16,39]. In particular, two earlier
studies highlight the potential of being able to elucidate a
better understanding of the effects of regulatory polymorphism
on the expression of genes essential to mental health [40,41].
Furthermore, the identification of these regulatory determi-
nants will, in turn, permit critical insights into the role of
epigenetic factors such as DNA methylation that are known
to influence gene expression. To date, however, there are very
few instances where specific low penetrance loci for ASD or
SCZ have been deemed worthy of modelling in animals or
human-induced pluripotent stem cell (hiPSC).
(c) Missing heritability
The majority of genetic risk for both SCZ and ASD is still to
be elucidated and is likely to involve many more rare high-
and low-risk factors, common low-risk factors, epistasis and
epigenetic interactions, the so-called missing heritability.
Their tiny effect sizes represent a formidable challenge: what
sort of clinical or behavioural phenotype if any should one
expect to find? A recent ‘omnigenic model’ has proposed that
gene regulatory networks are sufficiently interconnected,
such that all genes expressed in disease-relevant cells are
liable to affect the functions of core disease-related genes and
rstb.royalsociet
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side core pathways [42]. The genes we have chosen to discuss
here are likely to affect the function of core pathways and so
are likely to provide insights intowider populations of patients
with these disorders, even although themajority of patients are
not enriched for high-impact variants. ypublishing.org
Phil.Trans.R.Soc.B
373:201700373. Modelling: from mice to men
Two of the most important methods for attempting to model
neurodevelopmental disorders are genetically modified ani-
mals, especially rodent models, and in vitro modelling using
hiPSCs differentiated into neuronal precursors and, in turn,
to three-dimensional organoid systems. The advantages and
disadvantages of the twomethods are elegantly described else-
where [43], but are summarized below with modifications. It
cannot be stressed enough however that the full benefits of
modelling studies are predicated on knowing what phenotype
to expect and this depends on careful and deep phenotyping of
patients and individuals with mutations at the specific loci
under investigation. The enormous genetic heterogeneity
encountered in SCZ and ASD as well as locus pleiotropy
makes predictions of expected phenotype from population
findings alone much less satisfactory.
(a) Animal models: the pros and cons
Animal models of disruption exist for almost all human genes.
Coding regions of the genome are especially well preserved
and easier to model, whereas non-coding DNA, including
regulatory elements, show poor conservation across species.
The mouse genome is almost as well characterized as the
human and murine models have become relatively cost effec-
tive, straightforward to produce, and amenable to study at
molecular, cellular, circuit and behavioural levels. The advan-
tages of rat models are usually outweighed by the costs of
their generation and maintenance. The highest-throughput
and least-expensive models include zebrafish (Danio rerio)
and fruit fly (Drosophila melanogaster) [44], but obviously
these are unsuitable for modelling more complex human beha-
viours. Care must be given also to which mouse strain is used
as genetic background effects are potential confounders. How-
ever, there are a number of very obvious limitations and
drawbacks when using such models to study neuropsychiatric
disorders. Although there are established batteries to pheno-
type core features of ASD in mice [45], mice exhibit profound
differences in social behaviour from humans and furthermore,
even within mouse studies, variations in laboratory environ-
ments impose further variance. How these truly reflect the
human condition is debatable. Interpreting SCZ like pheno-
types in mice, including complex symptoms such as paranoia
and delusional beliefs, is even more challenging: they can
only be inferred indirectly from disordered mice behaviour, a
major limitation of modelling schizophrenia in animals.
(b) Human in vitro stem cell models: advantages and
limitations
Human iPSC technologies are allowing researchers to interro-
gate human cortical development in health and disease and
provide unlimited platforms of mature neuronal and glial cel-
lular subtypes and co-cultures for downstream studies such as
cellular physiology, phenotypic screening, and for drugdevelopment and screening. Such human iPSC models confer
a number of advantages including the fact that it is possible
to model for both coding and non-coding variants and, in
fact, it is also possible to model for disease without actually
knowing the causal genetic factor [46]. Clearly, though know-
ing the causal/contributory variants confers an advantage to
translational studies and a greater understanding of putative
mechanisms of disease [47]. It is possible to study the effects
of genomic mutations on brain development and in neuropsy-
chiatric disorders using clustered regularly interspaced short
palindromic repeats (CRISPR) gene-editing technologies. Pro-
teomics, transcriptomics, signalling and cell biology analysis
of isogenic-mutant paired lines at the neuronal stem cell and
differentiated neuron cell state offer unique opportunities.
However, limitations include heterogeneity and reproducibil-
ity issues arising from multiple sources, including culture
methodology and differences in lines and clones used. Further-
more, these hiPSC cultures produce immature fetal-like
neurons, limiting their potential to properly model later devel-
opmental stages. This, however, has become less of an issue as
it is now possible to mature cells by co-culture and also using
advanced organoid cultures [48,49], discussed further below.
(c) Towards three-dimensional cellular systems: growing
brain organoids
An organoid is a multicellular collection of cells that self-
organizes and develops from stem cell progenitors to resemble
the structure and function of an organ in vivo [50]. In vitro
models of the developing brain such as three-dimensional
brain organoids offer an unprecedented opportunity to study
aspects of human brain development and disease, in particular
the ability to follow development over time. Neuronal
migration, cortical lamination, projection patterns and circuit-
level organization are difficult to model in two-dimensional
cultures. Tissue engineering and three-dimensional organoid
cultures will enable the study of some of these phenotypes.
As mentioned earlier, rodent models have been heavily used
to study the cellular function of many of the genes implicated
in these disorders, especially those genes which are proposed
to have an important role in fundamental neurodevelopmental
processes such as cerebral cortex organization. However,
cortex development and organization is very different in
rodents compared to humans, so unsurprisingly neurodeve-
lopmental diseases cannot be consistently recapitulated in
animal models. This is all about to change as over the past
few years there have been further cutting-edge advances in
developmental neurobiology: we can now grow three-
dimensional cerebral organoid cultures from patient-derived
stem cells to study the early events of human brain develop-
ment. Proof-of-principle studies using human pluripotent
stem cell-derived three-dimensional organoid cultures have
allowed researchers to model human brain development and
microcephaly in a dish [51]. These ‘cerebral organoids’ develop
various discrete brain regions including a cerebral cortex that
produces functional cortical neuron subtypes capable of dis-
playing spontaneous synaptic transmission and producing
action potentials. Subsequent studies have also shown that it
is possible to develop region-specific identities, including neo-
cortex [52], telencephalon [53], cerebellum [54], neural tube
[55], pituitary [56], hippocampus [57], optic-cup [58] and
retina [59]. Through altering specific culture conditions, it is
possible to differentiate iPSC and embryonic stem cells (ESC)
a
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Figure 1. Overview of human iPSC model systems to study SCZ and ASD. Human iPSCs are generated by reprogramming fibroblasts from skin biopsies from
volunteers using a variety of techniques, most commonly using standard Yamanaka factors, delivered in non-integrative episomal vectors. Other starting cellular
materials can be used such as keratinocytes from hair or from peripheral blood mononuclear cells. Once generated and extensively tested, the hiPSCs can be used to
either make neuronal precursor cells or glial precursor cells (e.g. oligodendrocyte precursors) or grown and lifted to make three-dimensional organoids as shown in
frames (a) phase bright image of a cerebral organoid at two months of age and frame (b) shows an organoid that has been sectioned and stained with antibodies
to Pax6 and phospho-histone H3, clearly demonstrating a ventricular zone. The cellular platforms generated can then be used for further downstream studies
including electrophysiology, transcriptomic and proteomic studies, drug screening as well as morphological studies, and co-culturing with other cell types. In
addition, the hiPSCs can be gene-edited using CRISR–Cas9 to attempt to rescue phenotypes observed.
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GABAergic interneurons and glutamatergic neurons [61,62],
dopaminergic neurons [63], motoneuron [64] and glial pro-
genitors [65,66].
Most protocols adopted to generate cerebral organoids
depend on step-wise establishment of spatio-temporal strat-
egies using human ESC or iPSC (figure 1). The first stage
depends on the re-aggregation of iPSCs or ESCs in low-
adhesion conditions such as those provided by serum-free
embryoid body (EB) protocols, and allowing the cells enough
time to proliferate and expand [67,68]. During this initial
stage, the stem cells maintain pluripotency and the EBs that
form exhibit all three germ layers (ectoderm, mesoderm and
endoderm). The next stage involves neural induction where
the goal is to drive differentiation to neuroectoderm formation.
During these early stages, the initial organoids formed display
apical–basal and dorsal–ventral polarity and further induc-
tion can promote regional identity such that it is possible to
produce region-specific organoids [49]. The human cerebral
cortex is a well-defined structure with six layers of neurons:
superficial and deeper layers are connected to one another,
yet have distinct structural and functional projections and
fates [69,70]. One of the greatest challenges in the development
of the human cerebral cortex is the assembly of circuits com-
posed of glutamatergic neurons, generated in the dorsal
forebrain (pallium), and GABAergic interneurons arising in
the ventral forebrain (subpallium). However, it has recen-
tly been shown for the first time using a three-dimensionaldifferentiation approach using hiPSC to specify neural
spheroids and assemble these in vitro to model salutatory
migration of human interneurons towards the cerebral cortex
and functionally integrate into microcircuits [49].
Organoid cultures are, however, not without limitations:
spontaneous self-organization of cerebral organoids in culture
generates significant heterogeneity in cell type and structure,
with prolonged neotany in development and differentiation
limits their utility to early studies of brain development.
There are also challenges with scalability. However, with
modifications to culture systems such as the use of mini-reac-
tors [71] and microfluidics [72] combined with improved
seeding technologies (e.g. laminin-coated nanoparticles) [73],
it is possible to scale-up, improve consistency and robustness,
and reduce associated costs plus provide higher throughput
for drug screening. In this regard, iPSC-derived two-dimen-
sional and three-dimensional model systems hold potential
in future to screen drug targets for pharmaceutical develop-
ment (figure 1). Fundamentally, however, it is a human
in vitro system, and as such in vivo connectivity and external
milieu are not preserved, thus findingsmay not precisely trans-
late to in vivo biology experienced during human fetal brain
development. It is also important to remember that the
human brain develops both in utero and during the postnatal
period in an environment with inputs via sensory systems as
well as from neighbouring brain areas which collectively
helps to shape the cellular environment and circuits that
develop.Obviously, in vitro culture systems cannot recapitulate
rstb.royalsocietypublishing.org
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temperature, pH and chemical gradients. Furthermore, the
lack of neuromodulatory inputs to synaptic function may
preclude our ability to precisely study the effects of systems
such as the monoaminergic system in neuropsychiatric dis-
orders and limit their utility in drug development. Until
recently, anothermajor drawbackof organoids tomodel neuro-
developmental disorders was the unanswered questions as to
what extent they truly modelled regional complexity, cellular
diversity and circuit functionality of the brain. Gene expression
analysis in over 80 000 individual cells isolated from 31 human
brain organoids has shown that organoids generate a broad
diversity of cells, which are related to endogenous classes,
including cells from the cerebral cortex and retina [74]. Some
caution should be held, however, as to the relative quantities
of the different cell types generated in these organoid systems
and to what extent this reflects the quantities in the human
developing embryonic and fetal brain. In the Quadrato et al.’s
study [74], only two of 10 cell clusters analysed were found
to contain neurons from the cerebral cortex, accounting for
approximately 20% of cells examined, somewhat less than
what might be expected in vivo. Furthermore, these two cell
clusters were found in only 32% and 52% of all organoids
examined and within these populations approximately half
of the cells expressed the radial glial marker PAX6 after six
months, reflecting that they could not truly be classified as
wholly mature neurons. However, this study has allayed
fears that organoid cultures are limited by immaturity as a pro-
portion of the cells do appear more mature than has been seen
previously in culture. This team also elegantly demonstrated
that neuronal activity, within the organoid, could be controlled
using light stimulation of photosensitive cells which provides
further opportunity for the coupled use of optogenetics to
probe the functionality of human neuronal circuits and specifi-
callymodel higher-order functions of the human brain, such as
cellular interactions and neural circuit dysfunctions related to
neurodevelopmental and neuropsychiatric pathologies.4. Selection of loci for modelling of
neurodevelopmental disorders
(a) Single-nucleotide polymorphism-associated loci
In spite of their large numbers and widespread involvement in
SCZ and ASD, there have been few attempts to model individ-
ual common low-penetrant SNP-associated loci using either
animals or human iPSC technologies. This is unsurprising.
The vast majority of SNPs significantly associated in GWAS
are located outside gene-coding regions and, inmany instances,
often a considerable distance from the nearest coding region.
Most effort has, therefore, concentrated on attempting to fine
map putative functional variants presumed to be in linkage
disequilibrium with the GWAS-associated SNPs. This is paral-
leled by in silico bioinformatic investigations using pathway
analyses/gene ontology studies to try to obtain further corro-
boration of their functional significance. To date, success has
been very limited [33]. Fortunately, successful studies designed
to ascribe regulatory functionality to directly associated
SNPs, or those in linkage disequilibrium, using comparative
genomics and CRISPR-modified preclinical mouse models
are well underway. These studies promise to develop a better
understanding of the effects of regulatory polymorphism onthe expression of genes essential to mental health. Furthermore,
the identification of these regulatory determinants will, in turn,
permit critical insights into the role of epigenetic factors such as
DNAmethylation that are known to influence gene expression.
Two modelling attempts are worthy of note.
(1) The very strong allelic association of SCZ to themajor histo-
compatibility complex region of chromosome 6 prompted
detailed exploration of the putative involvement of complex
variation at the complement component 4 candidate gene.
In mice, the authors showed that some patterns led to
excess synaptic pruning [75], a dynamic process proposed
to rid the brain during the development of wasteful
neural connections and strengthen others, and proposed
to be a reason why brains from patients with SCZ have
fewer synaptic connections in multiple brain regions [76].
(2) The strong association of SNPs within CACNA1C with
autism, bipolar disorder and schizophrenia [36,77] has
been investigated functionally.
The risk-associated genotypes appear to affect RNA abun-
dance but results are inconclusive. CACNA1C has several
dozen exons, with multiple transcripts and promoters. The
locus is also independently associated with de novoMendelian
dominant exonic mutations responsible for Timothy syndrome
(TS), a neurodevelopmental disorder which has features of
ASD. The most interesting findings have emerged from study-
ing hiPSCs from individuals with TS [49,78]. Building on
previous work that showed in rodents that L-type calcium
channel (LTCC) genes play a critical role in interneuron
migration [79]. Birey et al. [49] found that cortical interneurons
derived from patients with TS display a cell-autonomous
migration defect whereby they move more frequently but
less efficiently [49]. What is more the TS interneuron defect is
rescued by pharmacologically manipulating LTCCs.(b) Rare highly penetrant genetic mutations
The selection of which high-penetrant genetic mutations to
model in mice or using hiPSC technologies poses separate
challenges from common low-risk SNP-associated loci.
Causative or non-causative?Often themutations are so rare that
statistical evidence of association with the disorder is lacking.
This is less of a problem in SCZwhere linkagewith the mutation
in multiplex families is often available for additional corrobora-
tion. Also through PGC and other consortia, DNA from many
thousands of cases is available for interrogation to try to identify
additional mutations at the locus of interest. In ASD, where
de novo mutation is more common, corroborating data from
multiplex families is usually not available. It can be argued that
de novomutation itself may support a causative role in a disorder
where the absence of familial cases is due to negative selection. A
word of caution is merited. It must be borne in mind that each
individual harbours approximately 60–100 de novo events [80],
and deciding which/if any are causative is not a trivial problem,
especially if it has implications for genetic counselling. Often,
therefore, one of the main purposes of modelling is to try to
demonstrate a causative mechanism that may result in the dis-
order under investigation. This especially applies where the
gene is not an obvious candidate for the disorder under investi-
gation, e.g. complement component 4 discussed above. In the
case of rare variants, biology does have a role in both establishing
a genetic association and later in understanding its role [81].
rstb.royalsocietypublishing.org
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evidence for involvement of the locus with the disorder is suf-
ficiently compelling that modelling in mice and/or hiPSCs
justifies the time and cost. Many such loci are currently being
examined using animal modelling and hiPSC technologies.
In these circumstances, the main questions concern what sort
of phenotype to expect at the different levels of analysis and
obviously also how to decide the precise nature of the model-
ling itself. The authors have been fortunate to have been
involved with the identification and/or analysis of several
loci that meet such criteria. These we discuss in more detail
below. They are (i) DISC1 and a key interactor NDE1 and
(ii) CYFIP1 and EIF4E genes which, with FXMR, encode for a
single molecular complex responsible for translation including
at the synapses in the brain.Soc.B
373:201700375. Disrupted in schizophrenia one
DISC1 is a major vulnerability factor for a wide range of
chronic mental illnesses, including SCZ [82]. DISC1 was
first isolated by cloning the breakpoints of a 1 : 11 balanced
translocation co-segregating with major psychiatric disorders
in a large Scottish pedigree [10,83]. Within this one family,
the logarithm of the odds (LOD) score for SCZ alone met
stringent genome-wide significance, while for SCZ plus
bipolar disorder and major depressive disorder, it substan-
tially exceeded genome-wide significance (multipoint
logarithm of odds ¼ 7.1). A second wave of follow-up con-
firmed these original findings [84]. Further evidence
supporting the involvement of DISC1 in mental disorders
has been more recently debated [81,85].
DISC1 expression in the brain is particularly high in the hip-
pocampus during neurogenesis and remains high in the adult
dentate gyrus, olfactory bulb and limbic regions [86,87], and
it appears that DISC1 regulates important developmental pro-
cesses such as neuronal migration, integration [88], synapse
formation and neuronal stem cell maturation [87,89–91].
DISC1 is thus critical for neurodevelopment and normal adult
neuronal function. In addition, transgenic or mutant mice
with impaired DISC1 function show brain morphological
changes, deficits in neural circuits, working memory impair-
ment and behavioural traits related to SCZ and also bipolar
disorder [92]. One of themore interesting of themice transgenic
models, denoted Disc1tr, expresses two copies of truncated
Disc1 encoding the first eight exons generated using a bacterial
artificial chromosome (BAC) [93]. With this partial simulation
of the human situation, they discovered a range of phenotypes
including a series of novel features not previously reported.
Disc1tr transgenic mice display enlarged lateral ventricles,
reduced cerebral cortex, partial agenesis of the corpus callosum
and thinning of layers II/IIIwith reduced neural proliferation at
mid-neurogenesis [93]. Parvalbumin (PVþ) GABAergic neur-
ons are reduced in the hippocampus and medial prefrontal
cortex, and displaced in the dorsolateral frontal cortex. In cul-
ture, transgenic neurons grow fewer and shorter neurites.
Behaviourally, these transgenic mice exhibit increased immo-
bility and reduced vocalization in depression-related tests,
and impairment in conditioning of latent inhibition. The BAC
mouse model uses the full mouse genomic sequence and natu-
ral promoters. Thismay be responsible for the considerable SCZ
reminiscent brain pathology observed in this study compared
to other studies using more artificial constructs.It is still not clear the mode of action of the t1 : 11
mutation. Haploinsufficiency seems most likely. No trun-
cated DISC1 protein has ever been identified, suggesting
elimination of mutated RNA by non-sense-mediated decay.
It has also been shown that transient knockdown of DISC1
by in utero electroporation in mouse, in the pre- and perinatal
stages, specifically in a lineage of pyramidal neurons mainly
in the prefrontal cortex, leads to selective abnormalities in
postnatal mesocortical dopaminergic maturation and behav-
ioural abnormalities associated with disturbed cortical
neurocircuitry after puberty [94]. Nevertheless, a dominant
negative mode of action from mutated DISC1 protein dimer-
izing with the wild-type cannot be ruled out. What is clear is
that the mutations reported in Disc1 do seem to alter the
structural organization of the DISC1 protein [95].
Themolecular and geneticmechanisms that are involved in
biological alterations can often be modelled in Drosophila or
zebrafish [44]. DISC1 causes associative memory and develop-
mental defects and disruption of sleep rhythms in Drosophila
[96,97]. In zebrafish studies, DISC1 variants were first ident-
ified from patient pools and tested in Disc1 loss-of-function
(LOF) mouse embryos to determine which could and which
could not rescue neuronal progenitor proliferation. When
they were injected in disc1 LOF zebrafish embryos, the variants
that showed maintenance or loss of activity in mice exhibited
similar patterns in rescuing or not, respectively, brain ventricle
and axon tract defects in zebrafish embryos [98]. These results
emphasize the conservation of variant function between
species, and indicate that a much higher number of variants
can be analysed in zebrafish than is feasible in the mouse.
It has also been possible to generate isogenic hiPSCs with
an engineered disease-relevant disruption of DISC1, which
affects neural progenitor cells (NPCs) proliferation, baseline
wingless-type mouse mammary tumor virus integration site
signalling and expression of NPC fate markers such as
FOXG1 and Tbr2 [99]. Ming & Song’s group have since gener-
ated hiPSCs from four members of an American family in
which a frameshift mutation of DISC1 co-segregated with
major psychiatric disorders [100] and furthermore produced
different isogenic iPS cell lines via gene editing [101]. In an ele-
gant series of experiments, they showed that mutant DISC1
causes synaptic vesicle release deficits in hiPSC-derived fore-
brain neurons [102–104]. Mutant DISC1 depleted wild-type
DISC1 protein and, furthermore, dysregulated expression of
many genes related to synapses and psychiatric disorders in
human forebrain neurons, providing new insights into themol-
ecular and synaptic etiopathology of psychiatric disorders
[101]. Although similar studies have not yet been published
from the Scottish DISC1 family, it will be interesting to see
whether synaptic dysregulation is also evident in neurons
derived from these hiPSCs.
Unlike in ASD, SCZ psychosis can be thought of as a neuro-
developmental disorder with psychosis as a late stage of illness,
even though several population-based studies indicate that the
problems are evident much earlier [105]. In this model of SCZ,
Insel proposes that reducedmyelination could alter connectivity
in SCZ. There are multiple studies showing white matter
changes in SCZ (reviewed in [106,107]) and specifically in the
DISC1 family [108]. It will be possible using hiPSC from the
DISC1 family to generate oligodendrocyte and astrocytes to
study the impact of glia on the pathophysiology. Insel also
argues that the trajectory of cognitive development in children
developing SCZ could include reduced elaboration of inhibitory
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to an altered excitatory–inhibitory balance in the prefrontal
cortex. In this regard, it will also be interesting to now use
hiPSC-derived GABAergic interneurons from the DISC1
families to specifically look for deficits in inhibitory interneuron
activityandN-methyl-D-aspartate receptorexpression. Protocols
are now available to generate GABAergic inhibitory inter-
neurons from hiPSC [109], which can be matured in culture to
generated PVþ interneurons for the electrophysiological study
of these cell types in vitro. Furthermore, as discussed earlier,
Birey et al. [49] have recently generated three-dimensional spher-
oids from hiPSC that resemble either the dorsal or ventral
forebrain and contain cortical glutamatergic or GABAergic
neurons [49]. This is a seminal study as it demonstrates for the
first time that it is nowpossible to generate organoids/spheroids
with network activity: these subdomain-specific forebrain
spheroids can be assembled in vitro to recapitulate the salutatory
migration of interneurons observed in the fetal forebrain. These
protocols will open the gates for the generation and studies of
human forebrain spheroids from hiPSC from patients with
other disease-associated mutations of SCZ and ASD.76. Nuclear distribution E homologue 1
NDE1 (nudE Nuclear Distribution E homologue 1) is a gene in
which different mutations result in a wide range of human
brain diseases including microcephaly [110], intellectual
disability [111], ASD [112], attention-deficit hyperactivity dis-
order (ADHD) [113] and SCZ [114–116]. NDE1 encodes a
cytoskeletal protein localizing to the centrosome that partici-
pates in essential neurodevelopmental processes, including
neuronal precursor proliferation and differentiation, neuronal
migration and neurite outgrowth [117]. NDE1 is part of the lis-
sencephaly-1/cytoplasmic dynein complex and as such
participates in regulation of cell proliferation, migration and
intercellular transport [118–132]. Cytoplasmic dynein is the
main molecular motor moving towards the minus ends of
microtubules, and is therefore responsible for carrying vesicles
and other entities from axon tips towards the cell bodies of
neurons (retrograde transport) [133–135].
Through protein–protein interaction, DISC1 regulates
NDE1 function: evidence supports a shared binding domain
for NDE1 and NDEL1 to DISC1, with opposite effects of the
DISC1 Ser704Cys mutation on binding patterns [129]. NDE1
and NDEL1 localize to the centrosome, and mutations in
both genes result in defective neurogenesis and neuronal
migration. This is proposed to arise from decoupling of the
centrosome from the nucleus as a result of defective microtu-
bule bundles connecting both organelles, and also from the
proposed role, all three genes have in regulating the cell cycle
and mitosis [122,136–138]. Furthermore, it has been shown
that familial mutations in NDE1 caused both severe failure of
neurogenesis and a deficiency of cortical lamination (microlis-
sencephaly) [110,139]. Elegant mouse studies have shown that
while cortical lamination is mostly preserved, the mutant
cortex has fewer neurons and very thin superficial cortical
layers (II– IV) [138]. BrdU birthdating revealed retarded and
modestly disorganized neuronal migration; however, more
dramatic defects on mitotic progression, mitotic orientation
and mitotic chromosome localization in cortical progenitors
were observed in Nde1 mutant embryos. Another Nde1
mutant mouse study has demonstrated catastrophic DNAdouble-strand breaks concurrent with DNA replication, lead-
ing to p53-dependent apoptosis and reduced neurons in
cortical layer II/III, and that this stalling of DNA replication
in the Nde1 mutants specifically occurred in mid-late S-phase
[140]. More recently, knockdown in rat using in utero electro-
poration confirmed these findings and shows that Nde1
effects are pronounced on premitotic nuclear migration with
specific effects on radial glial progenitor cells and on primary
cilia [141]. These studies elegantly demonstrate some of the
mechanisms whereby haploid reduction of Nde1 expression
may cause more subtle neurodevelopmental phenotypes.
It should be highlighted that although NDE1 does not
appear as a top GWAS ‘hit’, deletions and duplications span-
ning NDE1 (on Chromosome 16p13.11) are among the most
common CNVs in SCZ. CNVs in NDE1 have also been found
by others to associate with a range of phenotypically different
neurodevelopmental disorders including intellectual disability
[111], ASD [112], ADHD [113] and SCZ [111,114], which
suggest that the locus contains dosage-sensitive gene(s) that
may play a critical role in neurodevelopment. The deCODE
genetics study of 4345 SCZ patients and 35 079 controls from
eight European populations found a threefold excess of dupli-
cations and deletions at the 16p13.1 locus in SCZ cases,
comparedwith controls with duplications being far more com-
monly found [115]. In a Scottish population sample, we found
a fourfold excess of duplications at the 16p13.1 locus in SCZ
patients compared with controls [116]. Significant sex differ-
ences in prevalence, course and severity have been described
for a number of these conditions, but the biological and
environmental factors underlying such sex-specific features
remain unclear [142]. Rare SNPs in NDE1 have also been
shown to associate with SCZ susceptibility [143]. NDE1 has
also been identified as associating with psychosis proneness
in a large Finnish birth cohort upon re-analysis of GWAS link-
age data conditioned on a DISC1-associating risk haplotype
[144]. Thus, consistent with current neurodevelopmental con-
cepts in SCZ, the genetic and biological evidence for DISC1
and NDE1 provides evidence for a shared ‘risk’ pathway.
The underlying molecular mechanisms of the 16p13.11
microduplication, which despite being conserved across mice
and human species, have remained elusive. Ingason et al. [115]
subdivided the 16p13.1 region between 14.66 and 18.70 Mb
(Human Genome Build 36) into three single-copy sequence
intervals, denoted intervals I, II and III, each ofwhich is flanked
by sequences rich in low-copy repeats (LCRs). All duplications
and deletions so far reported are contained within this region,
with the most common breakpoints in the LCR clusters distal
to interval I and proximal to interval II (so-calledDup I þ II car-
riers) [115]. Dup I þ II carriers showed the highest common
odds ratio of all 16p13.11 microduplication carriers. The func-
tional implication of these variants in mental illness and the
mechanism of disease causation remain unknown, although
the potential of investigating this in neuronal cell types derived
from hiPSCs from specific patients hold much promise as has
been shown in a proof-of-principle studies modelling SCZ and
ASD using hiPSCs [43,46,47].
Despite the importance of studying neurodevelopmental
disorders and because data from human embryonic tissue are
scarce, there is a real challenge of finding an adequate model
system. Rodentmodels have been heavily used to study the cel-
lular function of Nde1, which revealed an important role of
NDE1protein in regulation of proliferation of neuronal progeni-
tors and neuronal migration retardation. However, cortex
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models and humans. In particular, the outer subventricular
zone, which is only present to a limited degree in rodents, is
populated by a unique stem cell subset termed outer radial
glia [145,146] that allow for the striking expansion in neuronal
output and brain size seen in humans. Therefore, it is not sur-
prising that neurodevelopment diseases cannot be
consistently recapitulated in animal models. However, as dis-
cussed earlier, the beauty and utility of hiPSC-derived
cerebral organoid will present a wealth of new possibilities to
thoroughly study the role of NDE1 in cellular proliferation,
migration and differentiation, in real time, in the human cer-
ebral cortex and allow the interrogation of genetic risk factors
hypothesized to play important roles in human corticogenesis..R.Soc.B
373:201700377. Cytoplasmic fragile X mental retardation 1–
interacting protein
Chromosome 15q11.2 CNVs have emerged as prominent risk
factors for various neuropsychiatric disorders, including SCZ,
autistic spectrum disorder and intellectual disability [147].
15q11.2 microdeletion (15q11.2 del) was identified as one of
the most frequent CNVs associated with increased risk for
SCZ [22], a finding subsequently confirmed in additional
cohorts [114,148,149]. 15q CNVs are not as penetrant as other
recurrent CNVs associated with neurodevelopmental dis-
orders. They are, however, under negative selection [22] and
even in normal subjects, and 15q11.2 del is associated with
cognitive variation and changes in structural measures on
MRI scanning [150]. 15q11.2 CNVs encompass four genes:
non-imprinted in Prader–Willi and Angelman 1 and 2
(NIPA1 and NIPA2), cytoplasmic fragile X mental retardation
1–interacting protein (CYFIP1) and TUBGCP5. While little is
known about functions of these genes in mammalian neural
development, CYFIP1 has been shown to interact with Rac1
[151], FMRP [152] and eIF4E [153]. Biochemical studies have
also identified CYFIP1 as a regulator of the WAVE complex,
consisting of WAVE1, WAVE2, Nap1 and Abi1, a complex
known to regulate Arp2/3- mediated actin polymerization
and membrane protrusion formation in non-neuronal cell
lines [151,154,155]. The function of WAVE signalling in
mammalian neurogenesis is not well understood. However,
an elegant study has been published using stem cells from
patients with 15q11.2 CNVs [47]. Yoon et al. [47] took a multifa-
ceted approach to investigatewhy 15q11.2 CNVs are prominent
risk factors for SCZ and ASD. Even in normal control subjects,
carriers of the 15q11.2 deletion have cognitive deficits and
structural changes on MRI scanning raising questions about
how this genetic variant brings about these changes in the car-
riers. They showed that hiPSC-derived neural progenitor cells
carrying 15q11.2 microdeletions exhibited deficits in adherens
junctions and apical polarity resulting from haploinsufficiency
of CYFIP1 [47]. Furthermore, they showed that deficiency in
CYFIP1 and WAVE in the developing mouse cortex affects
radial glial cell migration causing ectopic localization outside
of the ventricular zone [47]. Targeted humangenetic association
analyses revealed an epistatic interaction between CYFIP1 and
WAVE signalling mediator actin-related protein 2 and risk
for SCZ. Therefore, by integrating human neural stem cells,
in vivo animal modelling and targeted human genetic associ-
ation studies, a mechanistic understanding of how 15q11.2
microdeletions affect neural development has been uncovered.8. Eukaryotic translation initiation factor 4E
Eukaryotic translation initiation factor 4E (EIF4E) is the rate-limit-
ing component of eukaryotic translation initiation and plays a
key role in learning and memory through its control of trans-
lation within the synapse. EIF4E-mediated translation is the
final common process modulated by the mammalian target
of rapamycin (mTOR), phosphatase and tensin homologue
(PTEN) and fragile X mental retardation protein (FMRP) path-
ways, all of which are implicated in ASD [156,157]. Germline
mutations in PTEN human homologue are present in 1–5%
of patients with ASD, and PTEN knockout (KO) mice exhibit
cognitive impairment and deficits in social interaction which
are rescued by rapamycin [158]. Similarly, mutations in two
tuberous sclerosis genes (TSC1 and TSC2) cause ASD in a
subset of patients with tuberous sclerosis. Mice with deletions
of one copy of TSC1 or TSC2 genes also display deficits in
synaptic plasticity andmemory that are rescued by rapamycin.
The mTOR/Eif4E pathway is hyperactivated in fragile  syn-
drome (FS) patients, one of the leading genetic causes for
ASD spectrum disorder. In FS, a full mutation (greater
than 200 repeats) leads to hypermethylation of FMR1, an
epigenetic mechanism that silences FMR1 gene expression
and reduces levels of the FMR1 gene product, FMRP. The
absence of FMRP upregulates synaptic translation through fail-
ure of recruitment of CYFIP1, the EIF4E-binding protein [159].
The most well-characterized rodent model is the Fmr1 KO
mouse, which lacks FMRP protein due to a disruption in its
Fmr1 gene. These mice display a range of molecular, cellular,
tissue and behavioural abnormalities consistent with the
human phenotype, but the pattern and severity is variable
depending among other things upon the strain of mouse [160].
Linkage of ASD to the EIF4E region on chromosome 4q
was reported in genome-wide linkage studies [161] and was
subsequently directly implicated in ASD [162]. In a boy with
classic ASD, the authors observed a de novo balanced chromo-
some translocation between 4q and 5q and mapped the
breakpoint site to within a proposed alternative transcript
of EIF4E [162]. They then screened 120 ASD families for
mutations in EIF4E and found two unrelated families where
in each case both autistic siblings and one of the parents har-
boured the same single-nucleotide insertion at position 225 in
the basal element of the EIF4E promoter. Electrophoretic mobi-
lity shift assays and reporter gene studies show that this
mutation enhances binding of a nuclear factor and EIF4E pro-
moter activity. These genetic observations implicateEIF4E, and
more specifically control of EIF4E activity, directly in ASD.
They raised the exciting possibility that pharmacological
manipulation of EIF4E may provide therapeutic benefit
for those with ASD caused by disturbance of the converging
pathways controlling EIF4E activity.
These studies have been paralleled by molecular/cellular
and animal studies aimed at elucidating the key downstream
regulatory mechanisms responsible for so many upstream
forms of ASD as well as mutations in EIF4E itself. In the
brain, EIF4E activity is fundamental to the regulation of lasting
alterations in synaptic strength or plasticity, and of long-term
potentiation: these are important in learning and memory.
Increased activity in these systems can lead to repetitive, perse-
verative behaviour patterns. In mice KO of EIF4E-binding
protein (4E-BP2), an inhibitor of EIF4E leads to increased trans-
lation of neuroligins, also genetically implicated inASD [14], as
well as pathophysiological and behavioural abnormalities
rstb.royalsocietypublishing.org
Phil.Trans
9
 on January 23, 2018http://rstb.royalsocietypublishing.org/Downloaded from similar to those found in ASD. The phenotype was rescued by
pharmacological inhibition [163]. In a separate study, direct
overexpression of eIF4e in mice results in exaggerated cap-
dependent translation and a range of repetitive and persevera-
tive behaviours and social interaction deficits reminiscent of
autism. They are accompanied by synaptic pathophysiology
in medial prefrontal cortex, striatum and hippocampus. The
autistic behaviours are corrected by intracerebral infusion of
cap-dependent translation inhibitor 4EG1-1 [164]. In both
studies, pharmacological normalization of EIF4E activity recti-
fied many of the abnormalities observed in the mice [163,164].
These findings indicate that behavioural defects caused by
exaggerated cap-dependent translation are not irrevocable
and may be corrected well into adulthood..R.Soc.B
373:201700379. Conclusion
The remarkable complexity of the genetic architecture of SCZ
and ASD poses formidable challenges for clinicians and
scientists aiming to find methods to diagnose, sub-classify,
prevent and treat what were until recently considered incur-
able neurodevelopmental disorders. Over the last 10 years,however, a quiet revolution has been in progress: our under-
standing of key molecular pathways associated with SCZ and
ASD has increased in leaps and bounds as have methods for
modelling neurodevelopmental disorders in animals; this has
been paralleled by the new opportunities presented by hiPSC
technologies, especially when combined with CRISPR
editing, three-dimensional organoid development and
engraftment of in vitro technologies on to in vivo models; sev-
eral instances now exist where the worst symptoms of human
neurodevelopmental phenotypes can be arrested and/or
reversed at least in non-human animal models and with
in vitro hiPSC studies. This must surely be one of the most
promising areas of current psychiatric research.
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